Patent: 5,491,075
✉ Email this page to a colleague
Summary for Patent: 5,491,075
Title: | Cloning and expression of biologically active .alpha.-N-acetylgalactosaminidase |
Abstract: | The present invention involves the production of human .alpha.-GalNAc by cloning and expressing the .alpha.-GalNAc coding sequence in eukaryotic host cell expressions systems. The eukaryotic expression systems, and in particular the mammalian host cell expression systems described herein provide for the appropriate co-translational and post-translation modifications required or proper processing, e.g., glycosylation, phosphorylation, etc. and sorting of the expression product so that an active enzyme is produced. The .alpha.-GalNAc produced in accordance with the invention may be used in the treatment of Schindler disease or for the hydrolysis of .alpha.-N-acetylgalactosaminyl moieties in various glycoconjugates. |
Inventor(s): | Desnick; Robert J. (New York, NY), Bishop; David F. (New York, NY), Ioannou; Yiannis A. (New York, NY), Wang; Anne M. (New York, NY) |
Assignee: | The Mount Sinai School of Medicine of the City University of New York (New York, NY) |
Application Number: | 08/261,578 |
Patent Claims: | see list of patent claims |
Details for Patent 5,491,075
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Smith & Nephew, Inc. | SANTYL | collagenase | Ointment | 101995 | 06/04/1965 | ⤷ Try a Trial | 2013-02-13 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |